Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinqiao Xiaodu is a Traditional Chinese Medicine (TCM) preparation developed by the Beijing Institute of Traditional Chinese Medicine (Beijing Hospital of Traditional Chinese Medicine). It is a specialized hospital preparation primarily indicated for the treatment of influenza and acute upper respiratory tract infections characterized by symptoms such as fever, sore throat, and cough. The formula is composed of several medicinal herbs, most notably *Scutellaria baicalensis* (Huangqin) and *Forsythia suspensa* (Lianqiao), from which the name is derived. It functions by clearing heat and detoxifying the body, exhibiting broad-spectrum antiviral and anti-inflammatory properties. It has been utilized significantly in clinical practice in Beijing for managing viral respiratory diseases, including during major outbreaks such as H1N1 and COVID-19.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinqiao Xiaodu.